These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 27803740)

  • 21. The perivascular microenvironment in Epstein-Barr virus positive primary central nervous system lymphoma: The role of programmed cell death 1 and programmed cell death ligand 1.
    Sugita Y; Furuta T; Ohshima K; Komaki S; Miyoshi J; Morioka M; Abe H; Nozawa T; Fujii Y; Takahashi H; Kakita A
    Neuropathology; 2018 Apr; 38(2):125-134. PubMed ID: 29067721
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Checkpoint Inhibition: Programmed Cell Death 1 and Programmed Cell Death 1 Ligand Inhibitors in Hodgkin Lymphoma.
    Villasboas JC; Ansell S
    Cancer J; 2016; 22(1):17-22. PubMed ID: 26841012
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predictive factors of activity of anti-programmed death-1/programmed death ligand-1 drugs: immunohistochemistry analysis.
    Chakravarti N; Prieto VG
    Transl Lung Cancer Res; 2015 Dec; 4(6):743-51. PubMed ID: 26798583
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Manipulation of the Immune System for Cancer Defeat: A Focus on the T Cell Inhibitory Checkpoint Molecules.
    D'Arrigo P; Tufano M; Rea A; Vigorito V; Novizio N; Russo S; Romano MF; Romano S
    Curr Med Chem; 2020; 27(15):2402-2448. PubMed ID: 30398102
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expression patterns of programmed death-1 and programmed death-1 ligand-1 on T cells in gastric cancer.
    Kim JH; Kim SY; Shin EY; Jung JH; Choi HJ; Jun KH
    Oncol Lett; 2019 Sep; 18(3):2661-2669. PubMed ID: 31452748
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Predictive biomarkers for programmed death-1/programmed death ligand immune checkpoint inhibitors in nonsmall cell lung cancer.
    Remon J; Chaput N; Planchard D
    Curr Opin Oncol; 2016 Mar; 28(2):122-9. PubMed ID: 26756384
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure).
    Kim JM; Chen DS
    Ann Oncol; 2016 Aug; 27(8):1492-504. PubMed ID: 27207108
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Coinhibitory Molecule PD-1 as a Therapeutic Target in the Microenvironment of Multiple Myeloma.
    Atanackovic D; Luetkens T; Radhakrishnan S; Kroger N
    Curr Cancer Drug Targets; 2017; 17(9):839-845. PubMed ID: 28875836
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combined Radiotherapy and Anti-PD-L1 Antibody Synergistically Enhances Antitumor Effect in Non-Small Cell Lung Cancer.
    Gong X; Li X; Jiang T; Xie H; Zhu Z; Zhou F; Zhou C
    J Thorac Oncol; 2017 Jul; 12(7):1085-1097. PubMed ID: 28478231
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Juxtacrine Signaling Inhibits Antitumor Immunity by Upregulating PD-L1 Expression.
    Yang WH; Cha JH; Xia W; Lee HH; Chan LC; Wang YN; Hsu JL; Ren G; Hung MC
    Cancer Res; 2018 Jul; 78(14):3761-3768. PubMed ID: 29789418
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Value of Programmed Death Ligand 1 Expression in Cancer Patients Treated with Neoadjuvant Chemotherapy.
    Al-Dughaishi M; Shalaby A; Al-Ribkhi K; Boudaka A; Boulassel MR; Saleh J
    Sultan Qaboos Univ Med J; 2019 Nov; 19(4):e277-e283. PubMed ID: 31897310
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Programmed Death Ligand-1 (PD-L1) Expression in the Programmed Death Receptor-1 (PD-1)/PD-L1 Blockade: A Key Player Against Various Cancers.
    Guan J; Lim KS; Mekhail T; Chang CC
    Arch Pathol Lab Med; 2017 Jun; 141(6):851-861. PubMed ID: 28418281
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Polymorphism of the programmed death-ligand 1 gene is associated with its protein expression and prognosis in gastric cancer.
    Wu Y; Zhao T; Jia Z; Cao D; Cao X; Pan Y; Zhao D; Zhang B; Jiang J
    J Gastroenterol Hepatol; 2019 Jul; 34(7):1201-1207. PubMed ID: 30353572
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A review of the PD-1/PD-L1 checkpoint in bladder cancer: From mediator of immune escape to target for treatment.
    Zhou TC; Sankin AI; Porcelli SA; Perlin DS; Schoenberg MP; Zang X
    Urol Oncol; 2017 Jan; 35(1):14-20. PubMed ID: 27816403
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Epigenetic strategies synergize with PD-L1/PD-1 targeted cancer immunotherapies to enhance antitumor responses.
    Chen X; Pan X; Zhang W; Guo H; Cheng S; He Q; Yang B; Ding L
    Acta Pharm Sin B; 2020 May; 10(5):723-733. PubMed ID: 32528824
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety profiles of programmed cell death-1/programmed cell death ligand-1 inhibitors in the treatment of triple-negative breast cancer: A comprehensive systematic review.
    Lazarus G; Audrey J; Iskandar AWB
    Oncol Rev; 2019 Jul; 13(2):425. PubMed ID: 31857857
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Programmed death ligand-1/programmed death-1 inhibition therapy and programmed death ligand-1 expression in urothelial bladder carcinoma.
    Yu WB; Rao JY
    Chronic Dis Transl Med; 2019 Sep; 5(3):170-177. PubMed ID: 31891128
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Development of programmed death receptor-1 and programmed death receptor-1 ligand in oral squamous cell carcinoma].
    Chen ZH; Wu YD
    Hua Xi Kou Qiang Yi Xue Za Zhi; 2020 Aug; 38(4):449-453. PubMed ID: 32865367
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Results of clinical trials with anti-programmed death 1/programmed death ligand 1 inhibitors in lung cancer.
    Viteri S; González-Cao M; Barrón F; Riso A; Rosell R
    Transl Lung Cancer Res; 2015 Dec; 4(6):756-62. PubMed ID: 26798585
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immune checkpoint inhibition in ovarian cancer.
    Hamanishi J; Mandai M; Konishi I
    Int Immunol; 2016 Jul; 28(7):339-48. PubMed ID: 27055470
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.